

# GENOMICS PROTEOMICS and VACCINES

Editor  
**GUIDO GRANDI**

 **WILEY**

# Contents

|                                                                                                                        |            |
|------------------------------------------------------------------------------------------------------------------------|------------|
| <b>Preface</b>                                                                                                         | <b>xi</b>  |
| <b>List of contributors</b>                                                                                            | <b>xix</b> |
| <b>PART 1: INTRODUCTION</b>                                                                                            |            |
| <b>1 Vaccination: Past, Present and Future</b>                                                                         | <b>3</b>   |
| <i>Maria Lattanzi and Rino Rappuoli</i>                                                                                |            |
| 1.1 Introduction                                                                                                       | 3          |
| 1.2 Vaccination: the past                                                                                              | 4          |
| 1.3 Vaccination: the present                                                                                           | 6          |
| 1.4 Vaccination: the future                                                                                            | 12         |
| 1.5 Conclusion: the intangible value of vaccination                                                                    | 14         |
| References                                                                                                             | 15         |
| <b>2 Bioinformatics, DNA Microarrays and Proteomics in Vaccine Discovery: Competing or Complementary Technologies?</b> | <b>23</b>  |
| <i>Guido Grandi</i>                                                                                                    |            |
| 2.1 Introduction                                                                                                       | 23         |
| 2.2 From genome sequence to vaccine discovery                                                                          | 25         |
| 2.3 A case study: the anti-meningococcus B vaccine                                                                     | 28         |
| 2.4 Comparison of the three approaches                                                                                 | 34         |
| 2.5 Conclusions: a 'nomics' approach to vaccine discovery                                                              | 37         |
| References                                                                                                             | 40         |

**PART 2: TECHNOLOGIES**

|          |                                                                                                       |            |
|----------|-------------------------------------------------------------------------------------------------------|------------|
| <b>3</b> | <b>Genome Sequencing and Analysis</b>                                                                 | <b>45</b>  |
|          | <i>Hervé Tettelin and Tamara Feldeblyum</i>                                                           |            |
| 3.1      | Introduction                                                                                          | 45         |
| 3.2      | Genome sequencing                                                                                     | 46         |
| 3.3      | Genome analysis                                                                                       | 60         |
| 3.4      | Conclusion                                                                                            | 65         |
|          | References                                                                                            | 65         |
| <br>     |                                                                                                       |            |
| <b>4</b> | <b>Understanding DNA Microarrays: Sources and Magnitudes of Variances in DNA Microarray Data Sets</b> | <b>75</b>  |
|          | <i>She-pin Hung, Suman Sundaresh, Pierre F. Baldi and G. Wesley Hatfield</i>                          |            |
| 4.1      | Introduction                                                                                          | 75         |
| 4.2      | DNA array formats                                                                                     | 76         |
| 4.3      | Data analysis methods                                                                                 | 79         |
| 4.4      | Sources and magnitudes of noise in DNA microarray experiments                                         | 84         |
| 4.5      | Conclusions                                                                                           | 97         |
|          | Acknowledgements                                                                                      | 100        |
|          | References                                                                                            | 100        |
| <br>     |                                                                                                       |            |
| <b>5</b> | <b>The Proteome, Anno Domini Two Zero Zero Three</b>                                                  | <b>103</b> |
|          | <i>Pier Giorgio Righetti, Mahmoud Hamdan, Frederic Reymond and Joël S. Rossier</i>                    |            |
| 5.1      | Introduction                                                                                          | 103        |
| 5.2      | Some definitions                                                                                      | 105        |
| 5.3      | What methods exist to tackle the proteome complexity?                                                 | 107        |
| 5.4      | Quantitative proteomics                                                                               | 112        |
| 5.5      | Pre-fractionation in proteome analysis                                                                | 117        |
| 5.6      | Multi-dimensional chromatography                                                                      | 120        |
| 5.7      | Protein chip arrays                                                                                   | 123        |
| 5.8      | Imaging mass spectrometry                                                                             | 126        |
|          | Acknowledgements                                                                                      | 127        |
|          | References                                                                                            | 127        |

|                             |                                                                                                                                     |            |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------|
| <b>6</b>                    | <b>Mass Spectrometry in Proteomics</b>                                                                                              | <b>135</b> |
|                             | <i>Pierre-Alain Binz</i>                                                                                                            |            |
| 6.1                         | Introduction                                                                                                                        | 135        |
| 6.2                         | MS technology                                                                                                                       | 136        |
| 6.3                         | Principle of protein identification based on MS data                                                                                | 147        |
| 6.4                         | Proteomics workflows                                                                                                                | 155        |
|                             | References                                                                                                                          | 155        |
| <b>7</b>                    | <b>High Throughput Cloning, Expression and Purification Technologies</b>                                                            | <b>171</b> |
|                             | <i>Andreas Kreusch and Scott A. Lesley</i>                                                                                          |            |
| 7.1                         | Introduction                                                                                                                        | 171        |
| 7.2                         | Gene cloning                                                                                                                        | 172        |
| 7.3                         | Protein expression                                                                                                                  | 174        |
| 7.4                         | High-throughput protein purification                                                                                                | 175        |
| 7.5                         | Validation of the pipeline and outlook                                                                                              | 178        |
| 7.6                         | Conclusion                                                                                                                          | 179        |
|                             | References                                                                                                                          | 180        |
| <b>PART 3: APPLICATIONS</b> |                                                                                                                                     |            |
| <b>8</b>                    | <b>Meningococcus B: from Genome to Vaccine</b>                                                                                      | <b>185</b> |
|                             | <i>Davide Serruto, Rino Rappuoli and Mariagrazia Pizza</i>                                                                          |            |
| 8.1                         | Meningococcus, a major cause of bacterial meningitis                                                                                | 185        |
| 8.2                         | Group B meningococcus as an example of reverse vaccinology                                                                          | 190        |
| 8.3                         | Conclusions                                                                                                                         | 200        |
|                             | References                                                                                                                          | 201        |
| <b>9</b>                    | <b>Vaccines Against Pathogenic Streptococci</b>                                                                                     | <b>205</b> |
|                             | <i>John L. Telford, Immaculada Margarit y Ros, Domenico Maione, Vega Masignani, Hervé Tettelin, Giuliano Bensi and Guido Grandi</i> |            |
| 9.1                         | Introduction                                                                                                                        | 205        |
| 9.2                         | Comparative genomics of streptococci                                                                                                | 206        |
| 9.3                         | A vaccine against group B streptococcus                                                                                             | 208        |
| 9.4                         | A vaccine against group A streptococcus                                                                                             | 215        |
| 9.5                         | Conclusions                                                                                                                         | 218        |
|                             | References                                                                                                                          | 219        |

|           |                                                                                                                                     |            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------|------------|
| <b>10</b> | <b>Identification of the 'Antigenome' – a Novel Tool for Design and Development of Subunit Vaccines Against Bacterial Pathogens</b> | <b>223</b> |
|           | <i>Eszter Nagy, Tamás Henics, Alexander von Gabain and Andreas Meinke</i>                                                           |            |
| 10.1      | Introduction                                                                                                                        | 223        |
| 10.2      | Small DNA insert libraries – a tool to cover a pathogen's 'antigenome'                                                              | 227        |
| 10.3      | Proper display platforms                                                                                                            | 230        |
| 10.4      | Selected human sera to provide imprints of pathogen encounters                                                                      | 231        |
| 10.5      | Cognate antibodies reveal the 'antigenome' of a pathogen                                                                            | 234        |
| 10.6      | How to retrieve from the 'antigenome' the candidate antigens for vaccine development                                                | 235        |
| 10.7      | Summary and discussion                                                                                                              | 237        |
|           | References                                                                                                                          | 239        |
| <b>11</b> | <b>Searching the Chlamydia Genomes for New Vaccine Candidates</b>                                                                   | <b>245</b> |
|           | <i>Giulio Ratti, Oretta Finco and Guido Grandi</i>                                                                                  |            |
| 11.1      | Old problems and new perspectives for chlamydial vaccines                                                                           | 245        |
| 11.2      | Post-genomic approaches                                                                                                             | 250        |
| 11.3      | Genomic screening results                                                                                                           | 251        |
| 11.4      | Concluding considerations                                                                                                           | 262        |
|           | References                                                                                                                          | 263        |
| <b>12</b> | <b>Proteomics and Anti-Chlamydia Vaccine Discovery</b>                                                                              | <b>267</b> |
|           | <i>Gunna Christiansen, Svend Birkelund, Brian B. Vandahl and Allan C Shaw</i>                                                       |            |
| 12.1      | Introduction                                                                                                                        | 267        |
| 12.2      | Proteome analysis                                                                                                                   | 269        |
| 12.3      | Proteomics as a complement for genomics                                                                                             | 277        |
| 12.4      | Benefits that proteomics provide for vaccine development                                                                            | 279        |
|           | References                                                                                                                          | 280        |
| <b>13</b> | <b>Proteome Analysis of Outer Membrane and Extracellular Proteins from <i>Pseudomonas aeruginosa</i> for Vaccine Discovery</b>      | <b>285</b> |
|           | <i>Stuart J. Cordwell and Amanda S. Nouwens</i>                                                                                     |            |
| 13.1      | Introduction                                                                                                                        | 285        |

## CONTENTS

ix

|      |                                                |     |
|------|------------------------------------------------|-----|
| 13.2 | Membrane proteins in <i>P. aeruginosa</i>      | 286 |
| 13.3 | Extracellular proteins in <i>P. aeruginosa</i> | 292 |
| 13.4 | Immunogenic proteins and vaccine discovery     | 296 |
| 13.5 | Conclusions                                    | 298 |
|      | References                                     | 299 |

**Index**

**305**